Ovarian Cancer | Breakfast with the Investigators: Exploring the Role of PARP Inhibition in the Management of Ovarian Cancer

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Prof Jonathan A Ledermann and Drs Joyce F Liu and David M O’Malley. Introduction Program overview: Dr Love (00:00) Genetic Drivers of Ovarian Cancer Development and Current Testing Algorithms; PARP Inhibitors in the Management of Newly Diagnosed Disease (1:19) Case (Dr Liu): A woman in her early 60s who presented with gangrene of the fingers as a result of paraneoplastic syndrome and was found to have high-grade serous ovarian cancer (1:30) Case (Prof Ledermann): A woman in her early 70s with advanced ovarian cancer and a germline BRCA1 mutation who is a Jehovah’s Witness did not undergo debulking survey but enrolled on the SOLO-1 trial of maintenance olaparib (16:00) Case (Dr O’Malley): A woman in her 60s with Stage IIIC high-grade serous ovarian cancer with a somatic BRCA2 mutation who underwent optimal debulking surgery and received IP chemotherapy and maintenance olaparib (31:53) Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer (35:09) Case (Prof Ledermann): A nurse in her late 50s with BRCA wild-type, platinum-sensitive recurrent ovarian cancer who received niraparib maintenance therapy (43:03) Case (Dr Liu): A woman in her early 60s with multiply relapsed ovarian cancer and a germline BRCA2 mutation who received rucaparib monotherapy (49:46) Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development (57:09) Select publications